The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer.

Br J Cancer · 2019 · PMC6889376 · PMID 31530903

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Triple treatment showed a trend for survival benefit compared to single dose therapy (39 vs. 27 days median survival; n.s.).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.